GO:0010900 negative regulation of phosphatidylcholine catabolic process

Phosphatidylcholine (PC) is the most abundant glycerophospholipid in eukaryotic membranes and serves as a reservoir for choline, a precursor of the neurotransmitter acetylcholine and the osmolyte betaine. The catabolism of PC is carried out by phospholipases and lysophospholipases that hydrolyze the ester bonds of this lipid, releasing free fatty acids and water-soluble choline-containing products. The Gene Ontology term GO:0010900, negative regulation of phosphatidylcholine catabolic process, captures the biological processes that decrease the rate, frequency or extent of these catabolic reactions. Understanding this regulatory node is important because the steady-state level of PC must be tightly controlled to maintain membrane integrity, lipid signaling and systemic choline homeostasis. Research over the past decades has shown that PC catabolism is not merely a degradative housekeeping pathway but a finely tuned process that intersects with lipoprotein metabolism, mitochondrial function and cell survival. For example, cardiolipin and mitochondrial cristae organization depend on the availability of phospholipid precursors, and perturbations in phospholipid remodeling can alter mitochondrial bioenergetics. In addition, serum metabolomic profiling of subjects with non-alcoholic fatty liver disease (NAFLD) has revealed that dietary interventions such as n-3 polyunsaturated fatty acids and phytosterol esters can shift the lipidome, including PC species, in a manner that correlates with disease improvement. These observations underscore the need to identify the genes and regulatory mechanisms that suppress PC catabolism. At the cellular level, negative regulation of PC catabolism can be achieved by inhibiting phospholipase activity, by increasing reacylation of lysophosphatidylcholine back to PC, or by transcriptional and post-translational control of catabolic enzymes. The enzyme phosphatidylethanolamine N-methyltransferase (PEMT) is a key player in PC synthesis and indirectly influences the catabolic flux by altering the PC pool size. Moreover, lipidome characterization in type 1 and type 2 diabetes mellitus has identified sex-specific differences in PC species, suggesting that hormonal and metabolic contexts modulate the catabolic arm of PC metabolism. This article integrates authoritative GO annotation with verified PubMed literature to provide a research-grade overview of GO:0010900, its associated genes, disease relevance and experimental strategies.

GO:0010900, negative regulation of phosphatidylcholine catabolic process, is a biological process term defined as any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. In practical terms, this term covers molecular events such as inhibition of phospholipase A2 or phospholipase D activity, enhanced reacylation of lysophosphatidylcholine, or any regulatory signal that reduces the net degradation of PC. The term does not describe the catabolic reaction itself but the regulatory inputs that suppress it.

The negative regulation of phosphatidylcholine catabolism is critical because PC is not only a structural membrane component but also a signaling lipid and a source of choline for neurotransmitter synthesis. When this regulatory process fails, excessive PC breakdown can deplete membrane PC, impair mitochondrial function and disrupt lipid signaling, contributing to metabolic and neoplastic diseases. Conversely, enhancing negative regulation may protect cells from lipid peroxidation and ferroptosis, as suggested by studies on ACSL4-mediated phospholipid remodeling in cancer. Therefore, understanding GO:0010900 provides a mechanistic framework for developing therapeutic strategies that target phospholipid catabolic pathways.

The following genes and proteins are experimentally implicated in phosphatidylcholine metabolism, remodeling or its regulation, and serve as candidates for functional studies of GO:0010900.

The negative regulation of phosphatidylcholine catabolic process is controlled at multiple levels. Transcriptional regulation by nuclear receptors such as PPARα and SREBP1 modulates the expression of phospholipases and acyltransferases. Insulin signaling through the INSR/FOXO1 axis can suppress lipolytic gene expression, potentially reducing PC catabolism. Post-translational modifications, including phosphorylation and ubiquitination, control the stability and activity of phospholipases. Additionally, the availability of choline and other substrates influences the flux through catabolic pathways. Dietary factors such as n-3 PUFAs and phytosterol esters can alter the lipidome and may impact PC catabolism, as observed in NAFLD patients. However, the precise molecular mechanisms linking these systemic signals to GO:0010900 require further investigation.

NAFLD is characterized by excessive lipid accumulation in hepatocytes, including phosphatidylcholine species. A double-blind randomized controlled trial showed that n-3 PUFAs and phytosterol esters altered serum metabolomic profiles in NAFLD subjects, suggesting that dietary modulation of PC metabolism may be beneficial. Negative regulation of PC catabolism could reduce the release of free fatty acids and lysophospholipids that contribute to hepatic lipotoxicity and inflammation.

Lipidome characterization in type 1 and type 2 diabetes mellitus has revealed sex-specific differences in PC species, indicating that PC metabolism is altered in diabetic states. Insulin resistance may impair the negative regulation of PC catabolism, leading to increased breakdown and altered membrane composition. Targeting this pathway could improve lipid homeostasis in diabetes.

ACSL4-mediated membrane phospholipid remodeling induces integrin β1 activation and facilitates triple-negative breast cancer metastasis. This suggests that enzymes involved in PC remodeling and catabolism can promote aggressive cancer phenotypes. Negative regulation of PC catabolism might therefore be a double-edged sword: while it preserves membrane integrity, it could also support metastatic signaling depending on context.

Choline is essential for acetylcholine synthesis, and dietary choline is important for cognitive function. Excessive PC catabolism could deplete choline stores, impairing neurotransmission. Negative regulation of PC catabolism may help maintain cognitive health, although direct evidence linking GO:0010900 to neurodegeneration is still emerging.

Mass spectrometry-based lipidomics allows comprehensive quantification of phosphatidylcholine species and their catabolic products, such as lysophosphatidylcholine and free fatty acids. This method has been used to characterize lipidome changes in diabetes and NAFLD. By comparing wild-type and CRISPR-edited cells, researchers can determine whether a gene negatively regulates PC catabolism.

Phospholipase activity can be measured using fluorogenic or radioactive substrates. For example, PLA2 activity assays using radiolabeled PC allow direct assessment of catabolic rate. These assays are useful for validating hits from CRISPR screens and for determining the effect of point mutations on enzyme function.

Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate PC catabolism. A reporter cell line expressing a fluorescent PC analog or a choline-sensing biosensor can be used to sort cells with altered catabolic rates. Next-generation sequencing and bioinformatics then reveal candidate regulators, which can be validated individually.

Fluorescence microscopy with PC-binding probes (e.g., recombinant PLCδ1-PH domain) or tagged phospholipases can visualize PC distribution and catabolic events in live cells. Knock-in of fluorescent tags at endogenous loci enables tracking of enzyme localization and dynamics. This approach helps determine whether negative regulation occurs through spatial sequestration of PC or enzymes.

Researchers studying negative regulation of phosphatidylcholine catabolic process-related genes often need to determine whether a candidate gene is causally involved in suppressing PC breakdown or is merely correlated with lipidomic changes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from gene knockout to precise point mutations and library screening.

GO:0010900, negative regulation of phosphatidylcholine catabolic process, represents a critical regulatory node in lipid metabolism that safeguards membrane integrity and choline homeostasis. Dysregulation of this process is associated with metabolic diseases and cancer, making it a compelling area for functional genomics. By leveraging CRISPR-based models and multi-omics approaches, researchers can uncover the precise molecular mechanisms and therapeutic potential of targeting PC catabolism.